A Phase 2 Study of XmAb 20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer

Go Back to All Clinical Trials

A Phase 2 Study of XmAb 20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer

Brief description of study

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of XmAb20717 in patients with selected advanced gynecologic and genitourinary malignancies.

Clinical Study Identifier: s22-00496

ClinicalTrials.gov Identifier: NCT05032040

Other Investigators: David R. Wise, Kent Chan, Jaime Lynn Moyles, Scot Niglio, Deanna Gerber, Eva Chalas-Westermann, Olivia Richardson Khouri, Hank Ng, Marina Stasenko, Fabia Brisard Pierrot, Alexander A Hindenburg, Caitlin Elizabeth Ryan, Leslie R Boyd, Christina Grace Wilson, Michelle Diane Swanson Lightfoot, Emeline Mariam Aviki, Whitfield B. Growdon, Kelly A Levine, Victor Ricardo Adorno Febles, Minas Platon Economides, Edward A Jimenez, Erin Annette Reese, Bhavana Pothuri, Kathleen M Lutz.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies